Teladoc Health, Inc. (TDOC)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore is 2 (below the required floor of 3); the upstream qualitative screen flagged a red flag that blocks any new bullish entry, and no chart pattern overrides it.
Company overview
Teladoc Health, Inc. provides remote medical services globally, addressing a wide range of health needs from routine care to complex conditions like diabetes and mental health issues. The company offers virtual medical care, chronic disease management, and mental wellness support under brands such as Teladoc, Livongo, and BetterHelp. Founded in 2002 and based in Purchase, New York, it serves corporations, insurers, and individual patients.
Fundamental
fairTeladoc's fundamentals are mixed, with declining revenue and ongoing GAAP losses, but positive operating cash flow and low valuation multiples.
Mixed fundamentals: revenue has been drifting down and GAAP losses continue, but gross margins are high and operating cash flow has been positive. Liquidity looks adequate (large cash balance plus revolver availability), yet the BetterHelp slowdown and a $1B 2027 convertible maturity keep risk elevated. Low EV/Sales and EV/Adjusted-EBITDA multiples make it a turnaround candidate, not a high-conviction compounder.
Sentiment
weakSentiment is bearish following a Q2 earnings miss and a lowered BetterHelp outlook, despite a partnership with the NBA Players Union.
Dominant catalyst is the Q2 2026 earnings miss (announced, 2026-07-29) — revenue down 4% with a lowered BetterHelp outlook — which the market received bearishly, offset only by a modest NBA Players Union partnership win (announced, bullish). Sentiment delta is determinate deterioration (+0.27 baseline vs -0.03 scoring, moderate confidence on a thin two-item scoring window), and the Red-Flag Screen carries one moderate flag — conflicting catalyst signals — so the moderate red-flag cap applies.
Technical
weakThe stock is in a downtrend, with a weak bounce off oversold levels but no clear bullish reversal.
Price 6.47 sits below the SMA20 (6.56), SMA50 (7.81), SMA200 (6.69) and EMA21 (6.72), with a negative MACD line (-0.35) and ADX 28.4 confirming a dominant downtrend. RSI has recovered to 41.96 off late-August oversold lows (33.7 on 08-25), the MACD histogram has just turned positive (+0.07), and price reclaimed the EMA9 — but this is a stabilization bounce inside a broken structure, not a trend turn. Chart quality: mostly neutral-to-weak bearish, bounce-only, score 2/5.
You’re looking at 2026-09-03 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.